Kalden J R, Geiler T, Herrmann M, Bertling W
Medizinische Klinik III mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg.
Z Rheumatol. 1998 Jun;57(3):139-46. doi: 10.1007/s003930050072.
Based upon our increasing knowledge of mechanisms underlying tissue destruction in RA patients, new therapeutic principles have been developed, aimed at blocking proinflammatory cytokines or using antiinflammatory cytokines. Both principles, however, have proven to be very effective. In addition, the availability of the methodology to transduce cells with genes has initiated first experiments in animal models to test whether gene therapy for arthritis is suitable, followed by a first, very carefully formulated protocol for human RA. Gene therapy for RA has to still be considered as an experimental form of therapy in a very early stage, not allowing even now any serious treatment offer to RA patients. Several problems, such as the question of a suitable vector system have not yet been solved. With more experiments this therapeutic principle might become available and might prove effective even in a disease with a systemic character like RA in the coming years.
基于我们对类风湿关节炎(RA)患者组织破坏潜在机制的认识不断增加,已制定了新的治疗原则,旨在阻断促炎细胞因子或使用抗炎细胞因子。然而,这两种原则都已被证明非常有效。此外,用基因转导细胞的方法的出现,已在动物模型中开展了初步实验,以测试关节炎基因治疗是否合适,随后为人类RA制定了首个精心制定的方案。RA的基因治疗目前仍被视为处于非常早期的实验性治疗形式,甚至现在还不能为RA患者提供任何严肃的治疗方案。一些问题,如合适的载体系统问题尚未得到解决。通过更多实验,这种治疗原则可能在未来几年变得可行,甚至可能在像RA这种具有全身性特征的疾病中证明是有效的。